Muscarinic acetylcholine receptor M5: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 5: Line 5:


==Ligands==
==Ligands==
No highly selective agonists or antagonists for the M<sub>5</sub> receptor have been discovered as of 2009, but several non-selective muscarinic agonists and antagonists have significant affinity for M<sub>5</sub>.
No highly selective agonists or antagonists for the M<sub>5</sub> receptor have been discovered as of 2018, but several non-selective muscarinic agonists and antagonists have significant affinity for M<sub>5</sub>.


The lack of selective M5 receptor ligands is one of the main reasons that the medical community has such a limited understanding of the M5 receptors effects as the possibility that any and/or all effects of non-selective ligands may be due to interactions with other receptors can not be ruled out. Some data may be obtained by observing which effects are common among semi-selective ligands (ex. a ligand of M1 and M5, a ligand of M2 and M5, and a ligand of M3 and M5), but until both a selective agonist and a selective antagonist of the M5 receptor are developed this data must be considered merely theoretical.
The lack of selective M5 receptor ligands is one of the main reasons that the medical community has such a limited understanding of the M5 receptors effects as the possibility that any and/or all effects of non-selective ligands may be due to interactions with other receptors can not be ruled out. Some data may be obtained by observing which effects are common among semi-selective ligands (ex. a ligand of M1 and M5, a ligand of M2 and M5, and a ligand of M3 and M5), but until both a selective agonist and a selective antagonist of the M5 receptor are developed this data must be considered merely theoretical.
Line 16: Line 16:
* ML-380<ref name="pmid25147929">{{cite journal  |vauthors=Gentry PR, Kokubo M, Bridges TM, etal |title=Development of a Highly Potent, Novel M5 Positive Allosteric Modulator (PAM) Demonstrating CNS Exposure: 1-((1H-Indazol-5-yl)sulfoneyl)-N-ethyl-N-(2-(trifluoromethyl)benzyl)piperidine-4-carboxamide (ML380) |journal=J. Med. Chem. |volume= 57|issue= |pages= 7804–10|year=2014 |pmid=25147929 |doi=10.1021/jm500995y |pmc=4175000}}</ref>
* ML-380<ref name="pmid25147929">{{cite journal  |vauthors=Gentry PR, Kokubo M, Bridges TM, etal |title=Development of a Highly Potent, Novel M5 Positive Allosteric Modulator (PAM) Demonstrating CNS Exposure: 1-((1H-Indazol-5-yl)sulfoneyl)-N-ethyl-N-(2-(trifluoromethyl)benzyl)piperidine-4-carboxamide (ML380) |journal=J. Med. Chem. |volume= 57|issue= |pages= 7804–10|year=2014 |pmid=25147929 |doi=10.1021/jm500995y |pmc=4175000}}</ref>
* ML-326<ref name="pmid23562060">{{cite journal  |vauthors=Gentry PR, Bridges TM, Lamsal A, etal |title=Discovery of ML326: The first sub-micromolar, selective M5 PAM |journal=Bioorg. Med. Chem. Lett. |volume=23 |issue=10 |pages=2996–3000 |year=2013 |pmid=23562060 |doi=10.1016/j.bmcl.2013.03.032 |pmc=3634896}}</ref>
* ML-326<ref name="pmid23562060">{{cite journal  |vauthors=Gentry PR, Bridges TM, Lamsal A, etal |title=Discovery of ML326: The first sub-micromolar, selective M5 PAM |journal=Bioorg. Med. Chem. Lett. |volume=23 |issue=10 |pages=2996–3000 |year=2013 |pmid=23562060 |doi=10.1016/j.bmcl.2013.03.032 |pmc=3634896}}</ref>
* [[VU-0238429]]: [[Half maximal effective concentration|EC<sub>50</sub>]] = 1.16 μM; >30-fold selectivity versus M1 and M3, inactive at M2 and M4.<ref name="pmid19438238">{{cite journal  |vauthors=Bridges TM, Marlo JE, Niswender CM, etal |title=Discovery of the first highly M5-preferring muscarinic acetylcholine receptor ligand, an M5 positive allosteric modulator derived from a series of 5-trifluoromethoxy N-benzyl isatins |journal=J. Med. Chem. |volume=52 |issue=11 |pages=3445–8 |date=June 2009 |pmid=19438238 |doi=10.1021/jm900286j |url=}}</ref>
* [[VU-0238429]]: [[Half maximal effective concentration|EC<sub>50</sub>]] = 1.16 μM; >30-fold selectivity versus M1 and M3, inactive at M2 and M4.<ref name="pmid19438238">{{cite journal  |vauthors=Bridges TM, Marlo JE, Niswender CM, etal |title=Discovery of the first highly M5-preferring muscarinic acetylcholine receptor ligand, an M5 positive allosteric modulator derived from a series of 5-trifluoromethoxy N-benzyl isatins |journal=J. Med. Chem. |volume=52 |issue=11 |pages=3445–8 |date=June 2009 |pmid=19438238 |doi=10.1021/jm900286j |url=|pmc=3875304 }}</ref>


===Negative allosteric modulators===
===Negative allosteric modulators===
Line 70: Line 70:
{{DEFAULTSORT:Muscarinic Acetylcholine Receptor M5}}
{{DEFAULTSORT:Muscarinic Acetylcholine Receptor M5}}


[[Category:G protein coupled receptors]]
[[Category:G protein-coupled receptors]]
[[Category:Human proteins]]
[[Category:Human proteins]]
[[Category:Muscarinic acetylcholine receptors]]
[[Category:Muscarinic acetylcholine receptors]]

Revision as of 23:52, 6 November 2018

VALUE_ERROR (nil)
Identifiers
Aliases
External IDsGeneCards: [1]
Orthologs
SpeciesHumanMouse
Entrez
Ensembl
UniProt
RefSeq (mRNA)

n/a

n/a

RefSeq (protein)

n/a

n/a

Location (UCSC)n/an/a
PubMed searchn/an/a
Wikidata
View/Edit Human

The human muscarinic acetylcholine receptor M5, encoded by the CHRM5 gene, is a member of the G protein-coupled receptor superfamily of integral membrane proteins. It is coupled to Gq protein.[1] Binding of the endogenous ligand acetylcholine to the M5 receptor triggers a number of cellular responses such as adenylate cyclase inhibition, phosphoinositide degradation, and potassium channel modulation. Muscarinic receptors mediate many of the effects of acetylcholine in the central and peripheral nervous system. The clinical implications of this receptor have not been fully explored; however, stimulation of this receptor is known to effectively decrease cyclic AMP levels and downregulate the activity of protein kinase A (PKA).

Ligands

No highly selective agonists or antagonists for the M5 receptor have been discovered as of 2018, but several non-selective muscarinic agonists and antagonists have significant affinity for M5.

The lack of selective M5 receptor ligands is one of the main reasons that the medical community has such a limited understanding of the M5 receptors effects as the possibility that any and/or all effects of non-selective ligands may be due to interactions with other receptors can not be ruled out. Some data may be obtained by observing which effects are common among semi-selective ligands (ex. a ligand of M1 and M5, a ligand of M2 and M5, and a ligand of M3 and M5), but until both a selective agonist and a selective antagonist of the M5 receptor are developed this data must be considered merely theoretical.

Agonists

  • Milameline ((E)-1,2,5,6-Tetrahydro-1-methyl-3-pyridinecarboxaldehyde-O-methyloxime, CAS# 139886-32-1)
  • Sabcomeline

Positive allosteric modulators

Negative allosteric modulators

Antagonists

See also

References

  1. Kou Qin; Chunmin Dong; Guangyu Wu; Nevin A Lambert (August 2011). "Inactive-state preassembly of Gq-coupled receptors and Gq heterotrimers". Nature Chemical Biology. 7 (11): 740–747. doi:10.1038/nchembio.642. PMC 3177959. PMID 21873996.
  2. Gentry PR, Kokubo M, Bridges TM, et al. (2014). "Development of a Highly Potent, Novel M5 Positive Allosteric Modulator (PAM) Demonstrating CNS Exposure: 1-((1H-Indazol-5-yl)sulfoneyl)-N-ethyl-N-(2-(trifluoromethyl)benzyl)piperidine-4-carboxamide (ML380)". J. Med. Chem. 57: 7804–10. doi:10.1021/jm500995y. PMC 4175000. PMID 25147929.
  3. Gentry PR, Bridges TM, Lamsal A, et al. (2013). "Discovery of ML326: The first sub-micromolar, selective M5 PAM". Bioorg. Med. Chem. Lett. 23 (10): 2996–3000. doi:10.1016/j.bmcl.2013.03.032. PMC 3634896. PMID 23562060.
  4. Bridges TM, Marlo JE, Niswender CM, et al. (June 2009). "Discovery of the first highly M5-preferring muscarinic acetylcholine receptor ligand, an M5 positive allosteric modulator derived from a series of 5-trifluoromethoxy N-benzyl isatins". J. Med. Chem. 52 (11): 3445–8. doi:10.1021/jm900286j. PMC 3875304. PMID 19438238.
  5. Gentry PR, Kokubo M, Bridges TM, et al. (2013). "Discovery of the first M5-selective and CNS penetrant negative allosteric modulator (NAM) of a muscarinic acetylcholine receptor: (S)-9b-(4-chlorophenyl)-1-(3,4-difluorobenzoyl)-2,3-dihydro-1H-imidazo[2,1-a]isoindol-5(9bH)-one (ML375)". J. Med. Chem. 56 (22): 9351–5. doi:10.1021/jm4013246. PMC 3876027. PMID 24164599.
  6. Gentry PR, Kokubo M, Bridges TM, et al. (2014). "Discovery, Synthesis and Characterization of a Highly Muscarinic Acetylcholine Receptor (mAChR)-Selective M5 -Orthosteric Antagonist, VU0488130 (ML381): A Novel Molecular Probe". ChemMedChem. 9 (8): 1677–82. doi:10.1002/cmdc.201402051. PMC 4116439. PMID 24692176.
  7. Grant MK, El-Fakahany EE (October 2005). "Persistent binding and functional antagonism by xanomeline at the muscarinic M5 receptor". J. Pharmacol. Exp. Ther. 315 (1): 313–9. doi:10.1124/jpet.105.090134. PMID 16002459.

Further reading

This article incorporates text from the United States National Library of Medicine, which is in the public domain.